Tivozanib Treatment for Kidney Cancer

Tivozanib treatment for kidney cancer represents a notable advancement in the options available for patients, particularly since its approval by the U.S. Food and Drug Administration (FDA) in 2021. This development significantly enhances the therapeutic landscape for individuals with renal cell carcinoma (RCC), especially those dealing with advanced or metastatic disease.

Tivozanib is a potent, selective, and long-acting oral tyrosine kinase inhibitor (TKI). It primarily targets vascular endothelial growth factor receptors (VEGFRs), crucial in angiogenesis—the formation of new blood vessels vital for tumor growth and survival. Its mechanism of action disrupts the blood supply to the tumor, which can lead to tumor growth reduction and potential shrinkage.

The drug is indicated for advanced RCC treatment, especially in patients who have undergone two or more prior systemic therapies. Tivozanib has become a valuable option for patients who have shown limited responses to prior treatments, including other VEGFR-targeted therapies or immunotherapies.

Administered orally in capsule form, tivozanib offers ease of use and convenience for outpatient treatment. Dosage may be adjusted based on the patient's response and side effects experienced.

Clinical trials have demonstrated tivozanib's effectiveness in improving progression-free survival in patients with refractory advanced RCC. It has shown a favorable efficacy and safety profile compared to other available TKIs, positioning it as a promising option for previously treated patients with other systemic therapies.

Common side effects of tivozanib include hypertension, fatigue, diarrhea, decreased appetite, and dysphonia, along with hand-foot syndrome and proteinuria. Management strategies for these side effects typically involve dose adjustments, supportive care, and medications for specific symptoms like hypertension. Regular patient monitoring is crucial, including frequent blood pressure checks and side effect assessments. Regular imaging studies are also conducted to monitor treatment response and detect any signs of disease progression.

The FDA's 2021 approval of tivozanib for advanced RCC introduced a new therapeutic option for patients, particularly those with disease refractory to multiple lines of prior systemic therapy. Its high selectivity and efficacy profile mark it as a valuable addition to kidney cancer treatments, offering hope for improved outcomes in this challenging patient population.


Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791-3799. 


Popular posts from this blog

What Is Kidney Cancer?

Can Bladder Cancer be Prevented?

What is the Survival Rate for Bladder Cancer?

Prostate Cancer: An Overview

Urology Cancers Blog Disclaimer

Pembrolizumab for Renal Cell Carcinoma

How is Kidney Cancer Diagnosed?

What are the Risk Factors for Bladder Cancer?